Eli Lilly’s Obesity Drug Mounjaro Tops India’s Drug Sales in October

Eli Lilly’s weight-loss drug Mounjaro became India’s highest-selling medicine by value in October 2025, as per data from Pharmarack. The injectable drug reported sales of about ₹100 crore ($11.38 million) during the month, ahead of GlaxoSmithKline’s antibiotic Augmentin, which stood at ₹80 crore. Since its launch in March, Mounjaro’s total sales have reached around ₹333 crore.

Sales Volume and Price Gap

While Mounjaro led in value, Augmentin continued to dominate by volume. Around 5.8 million units of Augmentin were sold in October, compared to 85,000 units of Mounjaro. The gap shows Mounjaro’s higher price point. Pharmarack data showed that Mounjaro’s dose-wise consumption was about ten times higher than that of its rival Wegovy during the same period.

Market Comparison

In the anti-obesity category, Mounjaro’s October performance was ahead of other drugs. Wegovy recorded about ₹9 crore in sales, and Rybelsus reported ₹26 crore. Eli Lilly sold roughly 262,000 doses of Mounjaro in October, while Novo Nordisk sold 26,000 doses of Wegovy. Both drugs are part of the GLP-1 receptor agonist class, used to manage obesity and type 2 diabetes.

Product Launch and Pricing

Mounjaro was introduced in March in a vial format, priced between ₹3,000 and ₹4,000 per dose. A prefilled version called Kwikpen was later added, containing four doses priced between ₹20,000 and ₹25,000. The two formats allowed patients to begin treatment with smaller quantities and switch later to prefilled pens based on requirement.

Distribution and Demand

Mounjaro’s demand has been largely concentrated in metropolitan regions such as Mumbai and Delhi. Eli Lilly also entered an agreement with Cipla in October to sell the product under a separate brand name in India. The firm’s data showed that demand for anti-obesity drugs has been increasing steadily, supported by growing prescriptions in urban markets.

Read More: Eli Lilly & Novo Nordisk To Reduce Obesity Drug Prices After US Deal!

Conclusion

With October sales crossing ₹100 crore, Mounjaro replaced Augmentin as India’s top-selling drug by value, showing the rising use of newer metabolic and weight management treatments in the country.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.